#United States #Raleigh #Women's Health #Sprout Pharmaceuticals #Addyi

Recognition of Addyi in Women's Health

In a landmark event for women’s health, Sprout Pharmaceuticals has proudly announced that its flagship product, Addyi® (flibanserin), has been awarded the title of 'Best Prescription for Low Libido' in the 2026 Oprah Daily Menopause O-wards. This accolade is not just a recognition of the product itself but signifies a pivotal moment in the ongoing conversation surrounding women’s sexual health during menopause and midlife.

The Oprah Daily Menopause O-wards is a prestigious honor that highlights products making a substantial impact on the lives of women navigating menopause. Addyi's recognition is especially noteworthy in light of its recent expanded FDA approval, which now includes treatment for both premanopausal and postmenopausal women under the age of 65. This adjustment marks a significant step in making treatments for Hypoactive Sexual Desire Disorder (HSDD) more accessible and recognized in medical circles, encouraging healthcare providers to prioritize conversations about women's sexual health.

Cindy Eckert, the founder and CEO of Sprout Pharmaceuticals, commented on the importance of this recognition, stating, “This recognition matters because it finally puts sexual health where it belongs—at the center of the conversation on women's health and longevity.” Eckert emphasizes that women have often been instructed to overlook or minimize their experiences with changes in sexual desire, but the clinical evidence surrounding Addyi provides a legitimate medical framework to address these common issues.

The award comes on the heels of a significant regulatory change in December 2025, when the FDA broadened the approval of Addyi to encompass women aged under 65 with HSDD, regardless of their menopausal phase. Previously, approvals were limited, creating a gap in treatment options for many women. Now, healthcare providers have the support and assurance to prescribe Addyi, further solidifying its established safety and efficacy, which is backed by numerous clinical studies spanning over a decade.

This award also reflects a growing momentum in normalizing discussions about menopause and sexual health, which has long been overlooked in medical and media environments. Dr. Kelly Casperson, a board-certified urologist and sexual health expert, articulates the need for genuine treatment options for women facing desire changes. “When women are offered real treatment options, they get something priceless back — hope.”

Addyi has consistently been the most prescribed medication for HSDD since its FDA approval in 2015, illustrating its pivotal role in shaping the landscape of women’s sexual health. Sprout Pharmaceuticals is committed to not only providing effective treatment options but also fostering a culture that embraces evidence-based care and equality in women’s health.

Affordability and Accessibility of Addyi

Regarding access, Addyi is widely available and affordable. Most women with insurance typically pay an annual fee of $40, and those without can purchase it for $149 per month through mail-order pharmacy services. Furthermore, Addyi is available at over 70,000 retail pharmacies across the U.S., where patients can employ GoodRx coupons to make out-of-pocket costs more manageable.

Conclusion

As the conversation about women’s sexual health continues to evolve, awards like the Oprah Daily Menopause O-wards play a crucial role in raising awareness and presenting viable solutions such as Addyi. It encourages not only acceptance but also proactive discussions regarding women's health that historically have been pushed to the sidelines. The recognition of Addyi serves as both a celebration of progress and a reminder of the work that remains in establishing equitable healthcare for women, ensuring that their needs and concerns are acknowledged, addressed, and treated.

For more information about Addyi, or to begin a telehealth consultation, visit Addyi.com.